Polyneuropathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Polyneuropathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the safety and effectiveness of nucresiran and vutrisiran in patients with hereditary transthyretin amyloidosis with polyneuropathy https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-nucresiran-and-vutrisiran-in-patients-with-hereditary-transthyretin-amyloidosis-with-polyneuropathy/ Wed, 29 Apr 2026 15:09:07 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-nucresiran-and-vutrisiran-in-patients-with-hereditary-transthyretin-amyloidosis-with-polyneuropathy/ This study focuses on a rare condition called Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy. In this disease, an abnormal protein builds up in the body, which can cause damage to the nerves, leading to issues with movement and sensation. The purpose of the study is to evaluate the effectiveness and safety of a new medication called nucresiran.

Participants in the study will receive either nucresiran or vutrisiran, which is a currently used treatment for this condition. These medications are administered as a subcutaneous injection, meaning the medicine is injected into the fatty tissue just under the skin. During the study, the effects of these drugs on nerve function and the levels of a protein called transthyretin in the blood will be observed over time.

]]> Study on LY3848575 for Reducing Pain in Patients with Distal Sensory Polyneuropathy https://clinicaltrials.eu/trial/study-on-ly3848575-for-reducing-pain-in-patients-with-distal-sensory-polyneuropathy/ Wed, 29 Apr 2026 15:05:01 +0000 https://clinicaltrials.eu/trial/study-on-ly3848575-for-reducing-pain-in-patients-with-distal-sensory-polyneuropathy/ This clinical trial is focused on studying the effects of a new treatment for chronic neuropathic pain associated with a condition called distal sensory polyneuropathy. This condition involves nerve damage that causes pain, often in the hands and feet. The treatment being tested is a medication known by its code name, LY3848575, which is administered as a solution for injection under the skin. The study will compare the effects of LY3848575 to a placebo to see if it can reduce pain intensity in participants.

The purpose of the study is to determine if at least one dose of LY3848575 is more effective than a placebo in reducing pain. Participants in the study will receive either the medication or a placebo and will be monitored over a period to assess changes in their pain levels. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, ensuring unbiased results.

Throughout the study, participants will be asked to rate their pain using a simple scale, and the results will help researchers understand the potential benefits of LY3848575 for people suffering from chronic neuropathic pain. The study aims to provide valuable information that could lead to new treatment options for those affected by this painful condition.

]]> Study on Lacosamide and Duloxetine for Patients with Chemotherapy-Induced Neuropathic Pain https://clinicaltrials.eu/trial/study-on-lacosamide-and-duloxetine-for-patients-with-chemotherapy-induced-neuropathic-pain/ Wed, 29 Apr 2026 15:01:21 +0000 https://clinicaltrials.eu/trial/study-on-lacosamide-and-duloxetine-for-patients-with-chemotherapy-induced-neuropathic-pain/ This clinical trial is focused on studying the effects of two medications, lacosamide and duloxetine, in patients experiencing pain due to chemotherapy-induced neuropathy. Chemotherapy-induced neuropathy is a type of nerve damage that can occur after chemotherapy treatment, leading to pain and discomfort. The purpose of the study is to compare the pain-relieving effects of lacosamide, which is taken as film-coated tablets, and duloxetine, which is taken as hard gastro-resistant capsules.

Participants in the study will be randomly assigned to receive either lacosamide or duloxetine. The study will last for a period of eight weeks, during which the effectiveness of the medications in reducing pain will be observed. Participants will take the medication orally, and their pain levels will be monitored throughout the study. The study aims to determine if lacosamide is as effective as duloxetine in managing pain caused by chemotherapy-induced neuropathy.

In addition to assessing pain relief, the study will also evaluate patient satisfaction with the treatment and any side effects experienced. This information will help in understanding the overall benefits and potential drawbacks of each medication for individuals suffering from chemotherapy-induced neuropathy. The findings from this study could provide valuable insights into better pain management strategies for patients who have undergone chemotherapy.

]]> Study on Aconite Pain Oil to Prevent and Reduce Symptoms of Chemotherapy-Induced Polyneuropathy in Cancer Patients https://clinicaltrials.eu/trial/study-on-aconite-pain-oil-to-prevent-and-reduce-symptoms-of-chemotherapy-induced-polyneuropathy-in-cancer-patients/ Wed, 29 Apr 2026 14:26:33 +0000 https://clinicaltrials.eu/trial/study-on-aconite-pain-oil-to-prevent-and-reduce-symptoms-of-chemotherapy-induced-polyneuropathy-in-cancer-patients/ This clinical trial is focused on studying a condition known as chemotherapy-induced polyneuropathy (CIPN), which can occur in patients undergoing cancer treatment. The trial aims to explore the effectiveness of a treatment called Aconit Schmerzöl, also known as Aconite Pain Oil, in preventing and reducing the symptoms of CIPN. This condition can cause nerve damage, leading to symptoms like pain, tingling, and numbness, which can affect the quality of life. The study will compare the effects of Aconit Schmerzöl with a placebo to see if it can help reduce the risk of developing CIPN and improve the overall well-being of patients.

Participants in the study will be patients who are receiving chemotherapy treatments that include medications such as Taxanes and Carboplatin. These medications are commonly used in cancer treatment but can sometimes lead to CIPN. The trial will involve the use of Aconit Schmerzöl, which is applied externally, and aims to see if it can help prevent or lessen the severity of CIPN symptoms. The study will take place over a period of time, with regular assessments to monitor the effects of the treatment on the participants’ symptoms and quality of life.

The purpose of this study is to determine if Aconit Schmerzöl can effectively reduce the risk of CIPN and improve the quality of life for patients undergoing chemotherapy. By participating in this trial, researchers hope to gather valuable information that could lead to better management of CIPN symptoms in the future. The study will involve regular check-ups and assessments to track the progress and any changes in the participants’ condition, ensuring a comprehensive understanding of the treatment’s impact.

]]>